liraglutide 3.0 mg
liraglutide 3.0 mg is a pharmaceutical drug with 5 clinical trials. Historical success rate of 75.0%.
Success Metrics
Based on 3 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
1
Mid Stage
3
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
75.0%
3 of 4 finished
25.0%
1 ended early
0
trials recruiting
5
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients
EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial
Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.
Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin
Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans
Clinical Trials (5)
Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients
EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial
Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.
Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin
Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5